Biomedical research: Are we getting value for money?

Significance

Volumn 3, Issue 4, 2006, Pages 172-175

  Chalmers, Iain ^a,b  

^a James Lind Library   (United Kingdom)

^b Testing Treatments ^*

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37849189456     PISSN: 17409705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1740-9713.2006.00200.x     Document Type: Review

References (22)

1. UK Evaluation Forum (2006) Medical research: assessing the benefits to society. London: Academy of Medical Sciences, Medical Research Council and Wellcome Trust.
2. UK Clinical Research Collaboration (2006) UK Health Research Analysis. London: UKCRC
3. Comroe, J. H. and Dripps, R. D. (1976) Scientific basis for the support of biomedical science. Science, 192, 105-111.
4. Smith, R. (1987) Comroe and Dripps revisited. British Medical Journal, 295, 1404-1407.
5. Grant, J., Green, L. and Mason, B. (2003) From Bedside to Bench: Comroe and Dripps Revisited. Health Economics Research Group Report No. 30. Uxbridge, UK: Brunel University [Available at http://www.brunel.ac.uk/depts/herg/RR30.pdf]
6. Chalmers, I. (2000) Evaluating "pay back" on biomedical research: biomedical funding decisions should be audited. British Medical Journal, 321, 566.
7. Contopoulos-Ioannidis, D. G., Ntzani, E. and Ioannidis, J. P. (2003) Translation of highly promising basic science research into clinical applications. American Journal of Medicine, 114, 477-484.
8. Nightingale, P. and Martin, P. (2004) The myth of the biotech revolution. Trends in Biotechnology, 22, 564-569.
9. Silverman, W. A. (1983) The divisive effect of reductionist snobbery. Pediatric Research, 17, 518.
10. Rothwell, P. (2006) Funding for practice-orientated research. Lancet, 368, 262-266.
11. Tallon, D., Chard, J. and Dieppe, P. (2000) Relation between agendas of the research community and the research consumer. Lancet, 355, 2037-2040.
12. Warlow, C. J. (2003) Clinical trials for tomorrow funded by the MRC. British Medical Journal, 327, 240-241.
13. House of Commons Health Committee (2005) The Influence of the Pharmaceutical Industry. Fourth Report of the Session 2004-2005, Vol. II. London: Stationery Office.
14. Kirwan, J. R., Hewlett, S., Heiberg, T., Hughes, R. A., Carr, M., Hehir, M., Kvein, T., Minnock, P., Newman, S. P., Quest, E. M., Taal, E. and Wale, J. (2005) Incorporating the patient perspective into outcome assessment in rheumatoid arthritis - progress at OMERACT 7.Journal of Rheumatology, 32, 2250-2256.
15. Callahan, D. (2003) What price better health? Hazards of the research imperative. Berkeley: University of California Press.
16. Chalmers, I. (2005) The scandalous failure of science to cumulate evidence scientifically. Clinical Trials, 2, 229-231.
17. Clarke, M., Alderson, P. and Chalmers, I. (2002) Discussion sections in reports of controlled trials published in general medical journals. Journal of the American Medical Association, 287, 2799-2801.
18. Chalmers, I. (2006) From optimism to disillusion about commitment to transparency in the medico-industrial complex. Journal of the Royal Society of Medicine, 99, 337-341.
19. Cowley, A. J., Skene, A., Stainer, and Hampton, J. R. (1993) The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction. International Journal of Cardiology, 40, 161-166.
20. Moore, T. J. (1995) Deadly Medicine. New York: Simon and Schuster.
21. Global R&D Performance Metrics Programme: Industry Success Rates Report, CMR International, May 2005, p 7.
22. Hamblin, T. (2006) speaking on BBC Radio 4. File on 4, Sept. 26th.